Serina Therapeutics Files 8-K
Ticker: SER · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, corporate-update
TL;DR
Serina Therapeutics filed a routine 8-K on Oct 2nd, no major news.
AI Summary
Serina Therapeutics, Inc. filed an 8-K on October 2, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as AgeX Therapeutics, Inc. until June 6, 2017, is incorporated in Delaware and headquartered in Huntsville, Alabama. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing serves as a standard update for Serina Therapeutics, Inc., indicating routine corporate actions and disclosures to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no indication of significant events, financial distress, or material changes.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- AgeX Therapeutics, Inc. (company) — Former company name
- October 2, 2024 (date) — Date of report
- Huntsville, Alabama (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Serina Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits as of October 2, 2024.
When was Serina Therapeutics, Inc. formerly known by another name?
Serina Therapeutics, Inc. was formerly known as AgeX Therapeutics, Inc. until June 6, 2017.
Where are Serina Therapeutics, Inc.'s principal executive offices located?
Serina Therapeutics, Inc.'s principal executive offices are located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
What is the Standard Industrial Classification (SIC) code for Serina Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Serina Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Serina Therapeutics, Inc.?
The fiscal year end for Serina Therapeutics, Inc. is December 31 (1231).
Filing Stats: 607 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-10-02 08:30:41
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SER NYSE American Indic
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 21KB
- ex99-2.htm (EX-99.2) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 714KB
- ex99-1_002.jpg (GRAPHIC) — 1652KB
- ex99-1_003.jpg (GRAPHIC) — 457KB
- ex99-1_004.jpg (GRAPHIC) — 922KB
- ex99-1_005.jpg (GRAPHIC) — 874KB
- ex99-1_006.jpg (GRAPHIC) — 631KB
- ex99-1_007.jpg (GRAPHIC) — 940KB
- ex99-1_008.jpg (GRAPHIC) — 919KB
- ex99-1_009.jpg (GRAPHIC) — 795KB
- ex99-1_010.jpg (GRAPHIC) — 686KB
- ex99-1_011.jpg (GRAPHIC) — 968KB
- ex99-1_012.jpg (GRAPHIC) — 695KB
- ex99-1_013.jpg (GRAPHIC) — 985KB
- ex99-1_014.jpg (GRAPHIC) — 709KB
- ex99-1_015.jpg (GRAPHIC) — 1056KB
- ex99-1_016.jpg (GRAPHIC) — 931KB
- ex99-1_017.jpg (GRAPHIC) — 942KB
- ex99-1_018.jpg (GRAPHIC) — 802KB
- ex99-1_019.jpg (GRAPHIC) — 675KB
- ex99-1_020.jpg (GRAPHIC) — 794KB
- ex99-1_021.jpg (GRAPHIC) — 608KB
- ex99-1_022.jpg (GRAPHIC) — 900KB
- ex99-1_023.jpg (GRAPHIC) — 350KB
- ex99-2_001.jpg (GRAPHIC) — 23KB
- 0001493152-24-039111.txt ( ) — 26411KB
- ser-20241002.xsd (EX-101.SCH) — 3KB
- ser-20241002_lab.xml (EX-101.LAB) — 34KB
- ser-20241002_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: October 2, 2024 By: /s/ Steve Ledger Chief Executive Officer